16 results about "Teriflunomide" patented technology

The present invention relates to a novel topical pharmaceutical composition of Teriflunomide, comprising teriflunomide or its pharmaceutically acceptable salt in combination with pharmaceutically acceptable excipients, wherein the said composition is effective for use in treatment of pain associated with disorders like inflammation and arthritis. The composition is also useful for relieving the symptoms of pain and arthritis in subjects suffering from autoimmune diseases like multiple sclerosis or rheumatoid arthritis. The said topical composition of teriflunomide is prepared in the form of topical gel, topical cream, topical ointment, topical solution, lotion or topical spray with significantly enhanced permeability and diffusion rate of the drug.

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.

At least one pharmaceutical composition for use in a method of prophylaxis or treatment of COVID wherein the at least one pharmaceutical composition comprises donepezil, rivastigmine or galantamine or one of donepezil, rivastigmine or galantamine combined with one of: Artemether and Lumefantrine; Atazanavir Sulfate; Efavirenz; Fosamprenavir Calcium; Saquinavir; Remdesivir (GS-5734); Digoxin; Memantine; Rivastigmine; Galantamine; Valsartan; Teriflunomide and wherein the method of prophylaxis or treatment of COVID or COVID-19 comprises: providing a subject in need of said prophylaxis or treatment; providing the at least one pharmaceutical composition as defined supra; wherein said components are provided together or separately; wherein said components are administered together or separately; and wherein said components are provided in a pharmaceutically acceptable diluent, adjuvant and / or excipient; and administering a pharmaceutically effective amount of said at least one pharmaceutical composition to said subject; and wherein, in the method, said subject is provided prophylaxis or treatment of COVID and COVID relates to a human coronavirus, mouse hepatitis virus (MHV), or recombinant mouse-adapted SARS-CoV (SARS-CoV MAI 5).

The invention discloses an application of teriflunomide in preparation of a medicine for preventing and / or treating recurrent / refractory immune thrombocytopenia. According to the traditional Chinese medicine composition, the problem that relapse is difficult to treat in an existing ITP treatment scheme is solved, and the 24-week continuous remission rate of treating ITP patients with relapse and relapse difficult to treat can reach 50%. It is found for the first time that teriflunomide can be used as a candidate drug for ITP treatment to treat immune thrombocytopenia, and the teriflunomide has a good application prospect in the aspect of preventing or treating immune thrombocytopenia, especially in the aspect of recurrent / refractory immune thrombocytopenia.

The invention discloses a combined medicine for treating multiple sclerosis and containing a galanin receptor GAL2R agonist. The combined medicine comprises one or more medicines selected from glucocorticoid, teriflunomide, recombinant human beta-1b interferon, fingolimod and alendauzumab, and the galanin receptor GAL2R agonist. According to the invention, the galanin receptor GAL2R agonist is used in a combined manner, and different combined medicines are adopted in different disease courses of MS, so that the treatment effect of multiple sclerosis is improved, the recurrence rate and the disability progress are reduced, and the lifetime of a patient is prolonged.

The present invention relates to a pharmaceutical composition for preventing or treating anticancer drug-resistant cancer, containing teriflunomide as an active ingredient, wherein the teriflunomide can function as an immune checkpoint inhibitor by blocking the binding of PD-1 and PD-L1, and thus can be effectively used in medicines for preventing or treating cancer. In addition, the teriflunomide according to the present invention has an excellent anticancer effect against uterine sarcoma cancer that is resistant to doxorubicin, and thus can be very effectively used for preventing or treating resistant cancer.

This invention discloses a method for preparing teriflumine, comprising the step of reacting p-trifluoromethylaniline with 5-methylisoxazole-4-carboxylic acid in the presence of a catalyst; wherein the catalyst comprises one or more of EDC and CDI. This invention employs a one-pot reaction to directly obtain the teriflumine product, resulting in a significantly improved yield compared to existing methods. The raw materials and reagents used are inexpensive and readily available, the reaction conditions are mild, the operation is simple, and it is environmentally friendly, making it suitable for large-scale production.

The invention provides application of teriflunomide in preparation of a medicine for treating ovarian cancer and the medicine. The application provided by the invention can provide an effective, safe and drug-resistant ovarian cancer treatment drug for further treatment of ovarian cancer.

The present invention relates to a film coated tablet comprising teriflunomide, wherein the tablet comprising calcium stearate as lubricant and teriflunomide has a d (0.5) particle between 1 μm and 18 μm. Further the present invention discloses a method for the preparation of said tablet.

The present invention relates to a pharmaceutical combination comprising a first active ingredient which is ponesimod and a second active ingredient which is selected from the group consisting of teriflunomide and leflunomide.

Provided here are methods for treating a cytokine storm in a subject. One such method includes the administration of a therapeutically effective amount of an Insulin-like Growth Factor (IGF-1), a Ca2+-release-activated Ca2+ (CRAC) channel inhibitor, or combinations thereof. Methods include treatment of acute lung injury or acute kidney injury with a therapeutically effective amount of 3,5-bis(trifluoromethyl) pyrazole derivative or teriflunomide, either individually or in combination with IGF-1.

A method for determining an amount of teriflunomide in a sample by mass spectrometry includes adding an internal standard to the sample, subjecting the sample to solid phase extraction, purifying the sample by high turbulence liquid chromatography, ionizing the sample to produce one or more teriflunomide ions detectable by mass spectrometry, determining the amount of the one or more teriflunomide ions by mass spectrometry, and using the amount of the one or more ions determined to further determine the amount of teriflunomide in the sample.

The invention discloses a combined medicine for treating multiple sclerosis. The combined medicine comprises one or more medicines selected from glucocorticoid, teriflunomide, recombinant human beta-1b interferon, fingolimod and alendauzumab, and an NPYY1 receptor agonist. The invention further discloses a combined medicine composed of the NPYY1 receptor stimulant and glucocorticoid for treating acute-stage multiple sclerosis, and a combined medicine composed of the NPYY1 receptor stimulant and fingolimod for treating recurrent and progressive multiple sclerosis. The invention relates to a drug combination for treating recurrent progression type multiple sclerosis and secondary progression type multiple sclerosis, wherein the drug combination comprises an NPYY1 receptor agonist and teriflunomide and / or alendobuzumab. The combined medicine composed of the NPYY1 receptor agonist and the recombinant human beta-1b interferon is used for treating the recurrent progression type multiple sclerosis, and the clinical isolated syndrome of the multiple sclerosis is prompted by nuclear magnetic resonance imaging evidence.

The invention relates to develop a pharmaceutical tablet composition for oral administration, comprising Teriflunomide or а pharmaceutically ассерtаblе salt thereof, and а method for the preparation of said tablet with obtaining teriflunomide containing granules using wet granulation method and using a specific particle size distribution of Teriflunomide granules to provide content uniformity of tablets.